SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

Table 7 Change in serum aspartate aminotransferase levels in individual studies

Study	Serum AST levels (IU/L)			P value	P value between groups
	Group	Baseline	Study completion
Kuchay et al[11]	Empagliflozin	44.6 (23.5)	36.2 (9.0)	0.04	0.212
	Control	45.3 (24.3)	44.6 (23.8)	0.931
Ito et al[12]	Ipragliflozin	39.7 (16.7)	27.3 (8.9)	< 0.05	0.802
	Pioglitazone	43.3 (20.5)	32.4 (15.4)	< 0.05
Eriksson et al[14]	Placebo	29.4 (13.2)	-1.2 (7.2)1	-	-
	Omega-3 CA	30.6 (10.2)	+4.8 (9.0)1	-	Non-significant2
	Dapagliflozin	31.2 (11.4)	-4.2 (5.4)1	-	< 0.052
	O + D	30 (10.2)	+1.2 (5.4)1	-	Non-significant2
Ohki et al[15]	Ipragliflozin	37 (29.0-52.0)	28 (23.0-31.0)	0.03	-
Seko et al[16]	SGLT-2 inhibitor	54.4 (5.6)	38 (3.1)	0.001	-
	Sitagliptin	67 (7.7)	52.5 (7.7)	0.016
Gautam et al[17]	Canagliflozin	72 (16.7)	53 (10.3)	< 0.00001	-
Sumida et al[18]	Luseogliflozin	40.7 (22.2)	31.9 (18.2)	< 0.001	-

¹Change from baseline.

²Compared to placebo.

AST: Aspartate aminotransferase; CA: Carboxylic acid; O + D: Omega-3 carboxylic acid + Dapagliflozin; SGLT-2: Sodium glucose cotransporter-2.